Literature DB >> 11286708

RANTES: a versatile and controversial chemokine.

V Appay1, S L Rowland-Jones.   

Abstract

The activity of the chemokine RANTES is not restricted merely to chemotaxis. It is a powerful leukocyte activator, a feature potentially relevant in a range of inflammatory disorders. RANTES has attracted attention because it can potently suppress and, in some circumstances, enhance HIV replication. These characteristics are critically dependent on its ability to self-aggregate and bind to glycosaminoglycans.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11286708     DOI： 10.1016/s1471-4906(00)01812-3

Source DB:  PubMed          Journal:  Trends Immunol        ISSN： 1471-4906            Impact factor:   16.687


  198 in total

1.  Computationally identifying novel NF-kappa B-regulated immune genes in the human genome.

Authors:  Rongxiang Liu; Richard C McEachin; David J States
Journal:  Genome Res       Date:  2003-03-12       Impact factor: 9.043

2.  Analysis of differential immune responses induced by innate and adaptive immunity following transplantation.

Authors:  Hongzhen He; James R Stone; David L Perkins
Journal:  Immunology       Date:  2003-06       Impact factor: 7.397

Review 3.  Platelets: a critical link between inflammation and microvascular dysfunction.

Authors:  Karen Y Stokes; D Neil Granger
Journal:  J Physiol       Date:  2011-12-19       Impact factor: 5.182

4.  HIV-1 envelope protein gp120 up regulates CCL5 production in astrocytes which can be circumvented by inhibitors of NF-κB pathway.

Authors:  Ankit Shah; Dhirendra P Singh; Shilpa Buch; Anil Kumar
Journal:  Biochem Biophys Res Commun       Date:  2011-09-14       Impact factor: 3.575

5.  Relationship between inflammatory mediators, Aβ levels and ApoE genotype in Alzheimer disease.

Authors:  M Reale; M A Kamal; L Velluto; D Gambi; M Di Nicola; N H Greig
Journal:  Curr Alzheimer Res       Date:  2012-05       Impact factor: 3.498

6.  Clopidogrel reduces platelet-leucocyte aggregation, monocyte activation and RANTES secretion in type 2 diabetes mellitus.

Authors:  S A Harding; J Sarma; J N Din; P M Maciocia; D E Newby; K A A Fox
Journal:  Heart       Date:  2006-09       Impact factor: 5.994

7.  The strength of the chemotactic response to a CCR5 binding chemokine is determined by the level of cell surface CCR5 density.

Authors:  Caroline Desmetz; Yea-Lih Lin; Clément Mettling; Pierre Portalès; Herisoa Rabesandratana; Jacques Clot; Pierre Corbeau
Journal:  Immunology       Date:  2006-12       Impact factor: 7.397

8.  CCR5 expression on monocytes and T cells: modulation by transmigration across the blood-brain barrier in vitro.

Authors:  Eroboghene E Ubogu; Melissa K Callahan; Barbara H Tucky; Richard M Ransohoff
Journal:  Cell Immunol       Date:  2007-01-25       Impact factor: 4.868

9.  Chemokine binding protein vCCI attenuates vaccinia virus without affecting the cellular response elicited by immunization with a recombinant vaccinia vector carrying the HPV16 E7 gene.

Authors:  Pavel Gabriel; Katarina Babiarova; Kamila Zurkova; Jitka Krystofova; Petr Hainz; Luda Kutinova; Sarka Nemeckova
Journal:  Viral Immunol       Date:  2012-10       Impact factor: 2.257

10.  CXCR3 controls T-cell accumulation in fat inflammation.

Authors:  Viviane Zorzanelli Rocha; Eduardo J Folco; Cafer Ozdemir; Yuri Sheikine; Thomas Christen; Galina K Sukhova; Eva H C Tang; Marcio Sommer Bittencourt; Raul D Santos; Andrew D Luster; David E Cohen; Peter Libby
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-05-08       Impact factor: 8.311
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.